EFFECTS OF NANOCURCUMIN IN RATS WITH DIABETES INDUCED WITH STREPTOZOTOCIN AND NICOTINAMIDE: MRNA EXPRESSION OF B-TYPE NATRIURETIC PEPTIDE
Objective: This study aimed to determine the effects of nanocurcumin on cardiomyopathy, assessed by the expression of B-type natriuretic peptide
(BNP) mRNA in heart tissue.
Methods: Type 2 diabetic rats were induced with streptozotocin and nicotinamide. Nanocurcumin was orally administered (100 mg/kg/day)
for 30 days. BNP-45 mRNA expression in the heart tissue was measured using quantitative reverse transcription-polymerase chain reaction and
calculated using the Livak method.
Results: BNP-45 levels increased significantly (p<0.05) in diabetic rats compared with the normal group. Nanocurcumin treatment at a dose of
100 mg/kg for 30 days significantly decreased BNP-45 expression levels (p<0.05) compared with diabetic rats without treatment.
Conclusion: Nanocurcumin may be beneficial in inhibiting the progression of diabetic cardiomyopathy by suppressing the expression of BNP-45.
Publishing; 2014. p. 2323.
2. Indonesian Ministry of Health. Situation and Analysis of Diabetes.
Jakarta: Data and Information Center; 2014.
3. Waspadji S. Textbook of Internal Medicine. Jakarta: Internal Publishing; 2014.
4. Powers AC, In Harrisonâ€™s Endocrinology. 17th ed. New York: McGraw-
Hill; 2008. p. 267.
5. Shahab A. Texbook of Internal Medicine. Jakarta: Internal Publishing;
6. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE,
Duc P, et al. Rapid measurement of B-type natriuretic peptide in the
emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7.
7. Pappachan JM, Varughese GI, Sriraman R, Arunagirinathan G.
Diabetic cardiomyopathy: Pathophysiology, diagnostic evaluation and
management. World J Diabetes 2013;4:177-89.
8. Takei Y. B-Type natriuretic peptide (BNP) and C-type natriuretic
peptide (CNP). In: Handbook of Biologically Active Peptides. Vol. 10.
London: Elsevier; 2006. p. 805-12.
9. Jurenka JS. Anti-inflammatory properties of curcumin, a major
constituent of curcuma longa: A review of preclinical and clinical
research. Altern Med Rev 2009;14:141-53.
10. Jayaprakasha GK, Rao LJ, Sakariah KK. Antioxidant activities of
curcumin, demethoxycurcumin and bisdemethoxycurcumin. Food
11. Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R,
Phisalaphong C, Jirawatnotai S. Curcumin extract for prevention of
Type 2 diabetes. Diabetes Care 2012;35:2121-7.
12. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB.
Bioavailability of curcumin: Problems and promises. Mol Pharm
13. Ochekpe NA, Olorunfemi PO, Ngwuluka NC. Nanotechnology and
drug delivery Part 1: Background and applications. Trop J Pharm Res
14. Wang YJ, Lin HY, Wu CH, Liu DM. Forming of demethoxycurcumin
nanocrystallite-chitosan nanocarrier for controlled low dose cellular
release for inhibition of the migration of vascular smooth muscle cells.
Mol Pharm 2012;9:2268-79.
15. Nainggolan H. The Effect of Oral Nanokurkumin on Mice with Diabetic
Cardiomyopathy Focused on Oxidative Stress Resistance. Jakarta:
Pharmacology and Therapeutics Departement Faculty of Medicine
Universitas Indonesia; 2016.
16. Ferdinal F, Suyatna FD, Wanandi SI, Sadikin M. Expression of
B-type natriuretic peptide-45 (BNP-45) gene in the ventricular
myocardial induced by systemic chronic hypoxia. Acta Med Indones